Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT03650400
- Locations
- πΊπΈ
Novartis Investigative Site, San Antonio, Texas, United States
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)Biological: 13-valent pneumococcal conjugate vaccine (13-PCV)Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)Biological: Seasonal Quadrivalent influenza vaccineBiological: Keyhole limpet hemocyanin (KLH) neo-antigen
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1882
- Registration Number
- NCT03650114
- Locations
- πΊπΈ
BG Neurology, Spartanburg, South Carolina, United States
πΊπΈUpstate Clinical Trials LLC, Spartanburg, South Carolina, United States
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03647488
- Locations
- πΊπΈ
Highlands Oncology Group, Fayetteville, Arkansas, United States
πͺπΈNovartis Investigative Site, Madrid, Spain
Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: canakinumab-matching placebo
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 673
- Registration Number
- NCT03631199
- Locations
- πΊπΈ
Pacific Shores Medical Group ., Long Beach, California, United States
πΊπΈUSC Kenneth Norris Comprehensive Cancer Center ., Los Angeles, California, United States
πΊπΈAdvent Health Cancer Institute, Orlando, Florida, United States
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03628053
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Biological: Tisagenlecleucel
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT03630159
- Locations
- πΊπΈ
Emory University School of Medicine SC CTL019, Atlanta, Georgia, United States
πΊπΈUniversity of Kansas Hospital and Medical Center U of Kansas Cancer Center, Kansas City, Kansas, United States
πΊπΈUniversity of Chicago Medical Center Hematology and Oncology, Chicago, Illinois, United States
Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
- Conditions
- Asthma
- Interventions
- Drug: QAW039 150 mg once dailyDrug: QAW039 450 mg once dailyDrug: Placebo once daily
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 604
- Registration Number
- NCT03629249
- Locations
- π»π³
Novartis Investigative Site, Ho Chi Minh, Vietnam
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
- Conditions
- Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 245
- Registration Number
- NCT03626545
- Locations
- πΊπΈ
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
πΊπΈMontefiore Medical Center Albert Einstein College of Med, Bronx, New York, United States
πΊπΈEmory Winship Cancer Institute, Atlanta, Georgia, United States
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
- Conditions
- Multiple SclerosisRelapsing Multiple SclerosisAdvancing Multiple Sclerosis
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT03623243
- Locations
- π΅π·
Novartis Investigative Site, Guaynabo, Puerto Rico
πΊπΈMS & Neuromuscular Center of Excellence, Clearwater, Florida, United States
πΊπΈAlabama Neurology Associates, Homewood, Alabama, United States
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT03610516
- Locations
- πΉπ·
Novartis Investigative Site, Kocaeli, Turkey